Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3395 in Advanced Cancer
NCT02944864Phase 1Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2017
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQ-B3395 in solid tumor (advanced stage) and non-small cell lung cancer (NSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 48 weeks, Dose-Limiting Toxicity at 4 weeks and 5 more. Started Sep 2017; status: terminated.
02
Drugs
TQ-B3395
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02944864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02944864.